Nachrichten zur Merck & Co. Inc. Aktie

Why the Market Dipped But Merck (MRK) Gained Today

In the closing of the recent trading day, Merck (MRK) stood at $89.23, denoting a +1.86% change from the preceding…

Which Dow Jones Stock Is Cheaper, Amgen or Merck?

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group,…

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive

The European Commission approves MRKs pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.…

Is Merck Stock a Bargain Buy?

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda.…

Why Pfizer Is My Largest Healthcare Position

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the…

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $88.11, moving +0.27% from the previous trading session.…

Why Summit Therapeutics Stock Slipped Today

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on…

Pharmaindustrie: Bayer stärkt Forschung an Krebsmedikamenten mit Zukauf in China

Nach Deals von Merck und Novo Nordisk kauft nun auch Bayer in China zu. Ein neues Medikament soll Patienten mit…

Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative…

Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug

Merck has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the companies said on Tuesday, giving…

Is Summit Therapeutics a Millionaire Maker?

Multiple paths to immense wealth exist. A few lucky people win the lottery. Some start successful businesses. Others invest in…

2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

In the closing of the recent trading day, Merck (MRK) stood at $94.02, denoting a -0.74% change from the preceding…

Merck Loses Almost $52B in 6 Months: How to Play MRK Stock

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the…

Focus: Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to…

Notable healthcare headlines for the week: Merck, Novo Nordisk, J&J and Roche in focus

…

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the most-watched stock indexes on Wall Street. Its list of…

Down 93%, Is It Finally Time to Buy Moderna?

As we near the five-year anniversary of the COVID-19 pandemic, its a good time to revisit the drugmaker stock that…

Why Summit Therapeutics Stock Was Winning This Week

A very bullish analyst move was the news generally responsible for Summit Therapeutics (NASDAQ: SMMT) healthy mid-week stock price pop.…

Merck (MRK) Advances While Market Declines: Some Information for Investors

In the closing of the recent trading day, Merck (MRK) stood at $94.71, denoting a +1.46% change from the preceding…

Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note

Merck (MRK) closed the most recent trading day at $93.43, moving -1.37% from the previous trading session.…

Merck prevails in Gardasil safety litigation

A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil,…

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To…

2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger

Its time for another Market Cap Game Show. To catch full episodes of all The Motley Fools free podcasts, check…

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates,…

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ:…

Merck (MRK) Ascends While Market Falls: Some Facts to Note

Merck (MRK) closed at $94 in the latest trading session, marking a +0.87% move from the prior day.…

Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?

Merck (MRK) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

KORREKTUR/ROUNDUP 2: Merck will nach Aufschwung weiter profitabel wachsen

(Im letzten Absatz wir klargestellt, dass es sich um rund 70 rpt 70 Standorte handelt.) DARMSTADT (dpa-AFX)…

Boom um Künstliche Intelligenz treibt Merck an

Merck profitiert nicht nur vom Geschäft mit Arzneien, sondern auch vom Hype um Hochleistungschips. Selbst in schwächelnden Bereichen geht es…

DAX: Neues Rekordhoch – DHL Group, Dürr, GFT, Lufthansa, Merck, ProsiebenSat.1, Ströer und Zalando im Check

Der DAX knüpft am Donnerstag an die deutlichen Gewinne vom Vortag an und klettert im frühen Handel einmal mehr auf…

Pharmaindustrie: Pharma und KI-Materialien treiben Merck an – Zuversicht für 2025

Der Dax-Konzern profitiert von starken Geschäften mit Medikamenten und Halbleitermaterialien. Für 2025 rechnet Merck mit weiterem Wachstum – und steht…

Moderna anticipates 2027 release for cancer vaccine in collaboration with Merck By Investing.com

Moderna anticipates 2027 release for cancer vaccine in collaboration with Merck…

Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)

…

These Vanguard ETFs Show Where the Smart Money Is Moving Now

Dont discount the power of momentum. Some studies have found that momentum trading -- buying stocks or exchange-traded funds (ETFs)…

Prediction: 2 Brilliant Vanguard Index Funds Will Continue to Beat the S&P 500 in 2025

The S&P 500 (SNPINDEX: ^GSPC) is widely considered the best gauge for the overall U.S. stock market due to its…

Merck (MRK) Exceeds Market Returns: Some Facts to Consider

Merck (MRK) closed the most recent trading day at $92.25, moving +1.84% from the previous trading session.…

Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the…

Can Modernas Aggressive Cost Cuts Help Turn Things Around for Its Stock?

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.…

Mercks Oncology Strength: Beating Wall Street Again

…

US drugmaker Merck to boost workforce in India, executive says

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India…

US drugmaker Merck to boost workforce in India, executive says By Reuters

US drugmaker Merck to boost workforce in India, executive says…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Merck expects Keytruda to face HHS price setting in 2026

…

Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and Its Not Eli Lilly or Novo Nordisk

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly…

MERCK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MRK

SAN DIEGO, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

dpa-AFX ProFeed